| Schedule of Common Stock Equivalents were Excluded from Computation of Diluted Net Loss per Share |
The following common stock equivalents were excluded from the computation of diluted net loss per share attributable to common stockholders of BridgeBio, because including them would have been antidilutive: | | | | | | | | | | | | | | | As of June 30, | | 2026 | | 2025 | | | | Unvested RSUs | 9,074,136 | | 11,852,773 | | | | Unvested performance-based RSUs | 285,973 | | 194,943 | | | | Unvested market-based RSUs | 116,071 | | 375,000 | | | | Common stock options issued and outstanding | 10,041,746 | | 12,199,613 | | | Estimated shares issuable under performance-based milestone
compensation arrangements | 902,775 | | 1,681,209 | | | | Estimated shares issuable under the ESPP | 71,990 | | 112,977 | | | | Assumed conversion of 2027 Notes | 12,878,305 | | 12,878,305 | | | | Assumed conversion of 2029 Notes | 7,702,988 | | 7,702,988 | | | | Assumed conversion of 2031 Notes | 11,544,448 | | 11,544,448 | | | | Assumed conversion of 2033 Notes | 5,720,014 | | — | | | | 58,338,446 | | 58,542,256 | | |
|